title: Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results.
abstract: OBJECTIVE
  The aim of this study to describe the short-term anatomical results after an intravitreal injection of bevacizumab and triamcinolone acetonide in patients with foveal edema and/or subfoveal fluid associated with neovascularization (NV) due to age-related macular degeneration (AMD).
  
  
  METHODS
  A retrospective, noncomparative case series was conducted in patients with foveal edema and/or subfoveal fluid associated with NV due to AMD during a 3-month period. Patients were treated with intravitreal injections of bevacizumab (1.25 mg/0.05 mL) and followed immediately with triamcinolone acetonide (2 mg/ 0.05 mL) in separate syringes. Ophthalmoscopic examination with optical coherence tomography analysis of foveal edema and subfoveal fluid volume was performed at baseline and follow-up visits.
  
  
  RESULTS
  There were 30 consecutive eyes of 27 patients who received a short-term follow-up between 1 and 8 weeks after injection. Foveal thickness and subfoveal fluid volume were each statistically significantly reduced in the short term (paired Student t test; P < 0.01). No complications of intraocular pressure greater than 30 mmHg, endophthalmitis, retinal detachment, or vitreous hemorrhage developed.
  
  
  CONCLUSIONS
  Reduction of foveal edema and subfoveal fluid in patients with NV due to AMD suggests that combination treatment with intravitreal bevacizumab and triamcinolone merits further investigation.
authors.affiliation: Retina Department, South Jersey Eye Physicians, Moorestown, NJ 08057, USA. michael@macula.us
authors.forename: Michael
authors.initials: M
authors.lastname: Colucciello
mesh_terms: D000375:Aging / Q000502:physiology; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D006801:Humans; D007429:Intraocular Pressure; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology*; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide